ArticleEuropean journal of neurology2025
Anti-GAD Antibodies as an Etiology of Cerebral Cortical Encephalitis: 2 Case Reports.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCerebral cortical encephalitis (CCE) has been recently described as an entity associated with anti-MOG antibodies and, in some cases, of anti-GABA
methodIn two patients with CCE, screening for the presence of anti-GAD and other antibodies was performed, along with a complete workup for alternative diagnoses.
resultsTwo patients showing clinical and radiological features of CCE were tested positive for anti-GAD antibodies. MRI scan revealed multiple bilateral areas of cortico-subcortical FLAIR hyperintensities. They were both tested negative for anti-MOG, anti-NMDAr, and anti-GABA DISCUSSION: CCE could be a new manifestation of anti-GAD antibodies, with distinct features compared to anti-MOG antibodies related to CCE. We recommend screening for anti-GAD antibodies in the context of CCE, especially in case of atypical features for MOG antibodies-associated disease (MOGAD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.